About Lyell Immunopharma Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://lyell.com/
Frequently Asked Questions
What is the 52-week range for LYEL?
The 52-week high is $45 and the 52-week low is $9.36.
What is the P/E ratio for LYEL?
The P/E ratio data is currently unavailable.
What is the dividend yield for LYEL?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -91.62%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -920285.19%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 2.63.
Analyst Recommendation Trends
Wall Street analyst consensus for LYEL over the last few months:
Latest LYEL News
Lyell Immunopharma To Participate in the Baird 2026 Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, today announced that members of its senior management team will participate in the Baird 2026 Global Healthcare Conference on Tuesday, September 15, 2026, in New York with a fireside chat scheduled for 2:00 pm Eastern Time. A live webcast of the fire
Needham Reiterates Buy on Lyell Immunopharma, Maintains $44 Price Target
Needham analyst Gil Blum reiterates Lyell Immunopharma (NASDAQ:LYEL) with a Buy and maintains $44 price target.
Lyell Immunopharma Completes Manufacturing Transfer for LYL273 and Provides Updated Timeline on Phase 1/2 Trial in Metastatic Colorectal Cancer
Technology transfer to LyFE Manufacturing Center™ completed following FDA review of improved manufacturing process and updated analytical methodsDosing of additional patients with the new process at LyFE continues with the goal of determining the recommended Phase 2 dose and optimized safety management plan to support End-of-Phase 1 discussions with the FDAAdditional clinical data from the Phase 1/2 trial of LYL273 in patients with third- or later-line relapsed/refractory metastatic colorectal c
Lyell Immunopharma Completes Transfer For LYL273 Candidate To LyFE Manufacture Center In Washington
Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, today announced successful
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-09-10 | Aguirre Jarrad Mattieu | +47,500 | - | - |
| 2026-09-10 | Shook David | -500 | $12.7 | $6,350 |
| 2026-08-21 | Lee Gary K. | -1,457 | $15.54 | $22,642 |
| 2026-08-21 | Hill Stephen J. | -989 | $15.54 | $15,369 |
| 2026-08-21 | Seely Lynn | -9,589 | $15.54 | $149,013 |
| 2026-08-10 | Bulis Veronica Sanchez | -621 | $14.34 | $8,905 |
| 2026-08-10 | Lee Gary K. | -131 | $14.34 | $1,879 |
| 2026-08-10 | Hill Stephen J. | -89 | $14.34 | $1,276 |
| 2026-08-10 | Seely Lynn | -390 | $14.34 | $5,593 |
| 2026-07-27 | Innovative Cellular Therapeutics Holdings Ltd | -44,000 | - | - |
| 2026-07-27 | Innovative Cellular Therapeutics Holdings Ltd | -38,500 | - | - |
| 2026-07-17 | Innovative Cellular Therapeutics Holdings Ltd | -10 | $13.7 | $137 |
| 2026-07-16 | Innovative Cellular Therapeutics Holdings Ltd | -10 | $13.73 | $137 |
| 2026-06-29 | Innovative Cellular Therapeutics Holdings Ltd | -76,000 | - | - |
| 2026-06-10 | Bachleda Mark | +9,250 | - | - |
| 2026-06-10 | NABEL ELIZABETH G | +9,250 | - | - |
| 2026-06-10 | Klausner Richard | +9,250 | - | - |
| 2026-06-10 | Ramachandra Sumant | +9,250 | - | - |
| 2026-06-10 | FRIEDMAN CATHY | +9,250 | - | - |
| 2026-06-10 | BRAWLEY OTIS W | +9,250 | - | - |
| 2026-06-10 | RIEFLIN WILLIAM JL | +9,250 | - | - |
| 2026-06-10 | Shook David | -1,977 | $12.64 | $24,989 |
| 2026-05-11 | Bulis Veronica Sanchez | -217 | $18.91 | $4,103 |
| 2026-05-11 | Lee Gary K. | -130 | $18.92 | $2,460 |
| 2026-05-11 | Hill Stephen J. | -89 | $18.92 | $1,684 |
| 2026-05-11 | Seely Lynn | -388 | $18.91 | $7,337 |
| 2026-03-09 | Shah Smital | +140,000 | - | - |
| 2026-03-06 | ARCH Venture Fund IX, L.P. | +488,090 | $25.61 | $12,499,985 |
| 2026-03-06 | BERNS PAUL L | +488,090 | $25.61 | $12,499,985 |
| 2026-02-11 | Lee Gary K. | -1,671 | $23.39 | $39,085 |
| 2026-02-11 | Hill Stephen J. | -1,236 | $23.39 | $28,910 |
| 2026-02-11 | Seely Lynn | -7,455 | $23.39 | $174,372 |
| 2026-02-10 | Bulis Veronica Sanchez | -254 | $23.12 | $5,872 |
| 2026-02-10 | Bulis Veronica Sanchez | +8,750 | - | - |
| 2026-02-10 | Shook David | +50,000 | - | - |
| 2026-02-10 | Lee Gary K. | +50,000 | - | - |
| 2026-02-10 | Lee Gary K. | -147 | $23.12 | $3,399 |
| 2026-02-10 | Hill Stephen J. | +65,000 | - | - |
| 2026-02-10 | Hill Stephen J. | -109 | $23.12 | $2,520 |
| 2026-02-10 | Meltz Mark A | +50,000 | - | - |
| 2026-02-10 | Seely Lynn | +155,000 | - | - |
| 2026-02-10 | Seely Lynn | -438 | $23.12 | $10,127 |
| 2026-02-09 | Lee Gary K. | +4,000 | - | - |
| 2026-02-09 | Hill Stephen J. | +4,000 | - | - |
| 2026-02-09 | Seely Lynn | +20,000 | - | - |
| 2025-12-30 | Bulis Veronica Sanchez | -936 | $32.32 | $30,252 |
| 2025-12-24 | Bulis Veronica Sanchez | -1,136 | $38.67 | $43,929 |
| 2025-11-10 | Bulis Veronica Sanchez | -239 | $16.1 | $3,848 |
| 2025-11-10 | Lee Gary K. | -138 | $16.16 | $2,230 |
| 2025-11-10 | Hill Stephen J. | -95 | $16.12 | $1,531 |
| 2025-11-10 | Seely Lynn | -412 | $16.11 | $6,637 |
| 2025-10-27 | Lee Gary K. | +68,000 | - | - |
| 2025-10-27 | Hill Stephen J. | +75,000 | - | - |
| 2025-10-27 | Seely Lynn | +175,000 | - | - |